Bruce Westerman bought JNJ
Lloyd Doggett bought JNJ
Lloyd Doggett bought JNJ
Bill introduced
Jefferson Shreve bought JNJ
Jefferson Shreve bought JNJ
Committee on Health, Education, Labor, and Pensions. Hearings held.
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
| Registrant | Client | Amount | Filed | Period | Issues |
|---|---|---|---|---|---|
| AMERICA'S HEALTH INSURANCE PLANS, INC. (AHIP) | AMERICA'S HEALTH INSURANCE PLANS INC (AHIP) | $483.0M | Apr 21, 2025 | 2025Q1 | HCRMMMINS |
| BRISTOL-MYERS SQUIBB COMPANY | BRISTOL-MYERS SQUIBB COMPANY | $478.0M | Jul 21, 2025 | 2025Q2 | HCRMMMTAX |
| PFIZER INC. |
Congress members who traded stocks in companies connected to lobbying on this bill, within 90 days of its introduction date.
| Member | Party | Ticker | Company | Trade | Date | Amount | Timing | Lobbying Client | Conflict |
|---|---|---|---|---|---|---|---|---|---|
| Jefferson Shreve | R | JNJ | JOHNSON & JOHNSON | Buy | Mar 5, 2025 | $15,001 - $50,000 | Same day | JOHNSON & JOHNSON SERVICES INC | 36% |
| Jefferson Shreve | R |
100 trades by 16 members of Congress in companies connected to lobbying on S 864. The average conflict score is 32%.
CapitolExposed identifies the "bill-lobbying-trade pipeline" by: (1) finding lobbying filings (LD-2) that specifically mention this bill, (2) matching lobbying clients to publicly traded companies, and (3) finding stock trades by members of Congress in those companies within 90 days of the bill's introduction date. Trades made before the bill was introduced are highlighted in red, as they may indicate advance knowledge. This analysis surfaces correlations worthy of scrutiny; it does not prove wrongdoing.
Lobbying filed by AMERICA'S HEALTH INSURANCE PLANS INC (AHIP)
Lobbying filed by PFIZER INC.
Lobbying filed by NOVARTIS
Lobbying filed by PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION
Lobbying filed by BRISTOL-MYERS SQUIBB COMPANY
| PFIZER INC. |
| $424.0M |
| Apr 21, 2025 |
| 2025Q1 |
BUDHCRMMM |
| NOVARTIS | NOVARTIS | $416.8M | Apr 21, 2025 | 2025Q1 | BUDCPTHCR |
| PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION | PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION | $411.3M | Apr 21, 2025 | 2025Q1 | MMMHCRPHA |
| AMERICA'S HEALTH INSURANCE PLANS, INC. (AHIP) | AMERICA'S HEALTH INSURANCE PLANS INC (AHIP) | $405.0M | Jul 21, 2025 | 2025Q2 | HCRMMMINS |
| THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) | THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) | $346.0M | Apr 21, 2025 | 2025Q1 | MMMHCRDEF |
| CVS HEALTH (AND SUBSIDIARIES) | CVS HEALTH (AND SUBSIDIARIES) | $346.0M | Apr 21, 2025 | 2025Q1 | PHATAXMMM |
| PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION | PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION | $342.9M | Jul 21, 2025 | 2025Q2 | MMMHCRPHA |
| JOHNSON & JOHNSON SERVICES, INC. | JOHNSON & JOHNSON SERVICES INC | $334.0M | Apr 21, 2025 | 2025Q1 | PHASCITAX |
| SANOFI US SERVICES INC. | SANOFI US SERVICES INC | $254.0M | Apr 21, 2025 | 2025Q1 | MANHCRMMM |
| ABBVIE, INC. | ABBVIE INC. | $211.0M | Apr 21, 2025 | 2025Q1 | CPTHCRMMM |
| AMERICAN CANCER SOCIETY CANCER ACTION NETWORK, INC. | AMERICAN CANCER SOCIETY CANCER ACTION NETWORK INC | $198.0M | Apr 21, 2025 | 2025Q1 | HCRTAXTOB |
| THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) | THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) | $189.0M | Jul 21, 2025 | 2025Q2 | MMMHCRDEF |
| VERTEX PHARMACEUTICALS INCORPORATED | VERTEX PHARMACEUTICALS INCORPORATED | $160.0M | Apr 18, 2025 | 2025Q1 | MMMTAXBUD |
| GSK (FKA GLAXOSMITHKLINE INC.) | GSK (FKA GLAXOSMITHKLINE INC.) | $151.0M | Jul 21, 2025 | 2025Q2 | BUDCPTHCR |
| ABBVIE, INC. | ABBVIE INC. | $116.0M | Jul 21, 2025 | 2025Q2 | CPTHCRMMM |
| VERTEX PHARMACEUTICALS INCORPORATED | VERTEX PHARMACEUTICALS INCORPORATED | $114.0M | Jul 16, 2025 | 2025Q2 | HCRMMMTAX |
| SANOFI US SERVICES INC. | SANOFI US SERVICES INC | $105.0M | Jul 21, 2025 | 2025Q2 | HCRMMMTRD |
| JOHNSON & JOHNSON SERVICES, INC. | JOHNSON & JOHNSON SERVICES INC | $103.0M | Jul 21, 2025 | 2025Q2 | HCRBUDCPT |
| EMD SERONO, INC. | EMD SERONO INC | $91.0M | Jul 21, 2025 | 2025Q2 | HCRMMMPHA |
| EMD SERONO, INC. | EMD SERONO INC | $90.0M | Apr 21, 2025 | 2025Q1 | SCITRDHCR |
| BIOTECHNOLOGY INNOVATION ORGANIZATION | BIOTECHNOLOGY INNOVATION ORGANIZATION | $89.0M | Apr 21, 2025 | 2025Q1 | AGRANIBUD |
| NOVARTIS | NOVARTIS | $88.0M | Jul 21, 2025 | 2025Q2 | BUDCPTHCR |
| GSK (FKA GLAXOSMITHKLINE INC.) | GSK (FKA GLAXOSMITHKLINE INC.) | $80.0M | Apr 21, 2025 | 2025Q1 | BUDCPTHCR |
| ASSOCIATION FOR CLINICAL ONCOLOGY | ASSOCIATION FOR CLINICAL ONCOLOGY | $65.0M | Jul 17, 2025 | 2025Q2 | MMMHCRTOB |
| AMERICAN ACADEMY OF OPHTHALMOLOGY | AMERICAN ACADEMY OF OPHTHALMOLOGY | $42.8M | Apr 21, 2025 | 2025Q1 | HCRVETDEF |
| CYSTIC FIBROSIS FOUNDATION | CYSTIC FIBROSIS FOUNDATION | $30.0M | Jul 21, 2025 | 2025Q2 | HCRINSBUD |
| ASSOCIATION FOR CLINICAL ONCOLOGY | ASSOCIATION FOR CLINICAL ONCOLOGY | $25.0M | Apr 17, 2025 | 2025Q1 | MMMHCRTOB |
| AMERICAN ACADEMY OF OPHTHALMOLOGY | AMERICAN ACADEMY OF OPHTHALMOLOGY | $20.7M | Jul 21, 2025 | 2025Q2 | HCRVETDEF |
| CYSTIC FIBROSIS FOUNDATION | CYSTIC FIBROSIS FOUNDATION | $20.0M | Apr 21, 2025 | 2025Q1 | HCRINSBUD |
| AMERICAN COLLEGE OF RHEUMATOLOGY | AMERICAN COLLEGE OF RHEUMATOLOGY | $18.0M | Jul 21, 2025 | 2025Q2 | HCRBUDMMM |
| EPILEPSY FOUNDATION | EPILEPSY FOUNDATION | $16.0M | Apr 18, 2025 | 2025Q1 | BUDHCRCIV |
| THE SUSAN G. KOMEN BREAST CANCER FOUNDATION, INC. DBA SUSAN G. KOMEN | THE SUSAN G. KOMEN BREAST CANCER FOUNDATION, INC. DBA SUSAN G. KOMEN | $11.0M | Apr 21, 2025 | 2025Q1 | BUDINSMMM |
| TODD STRATEGY GROUP | ALEXION PHARMACEUTICALS, INC. | $8.0M | Jul 19, 2025 | 2025Q2 | MMMHCR |
| AMERICAN COLLEGE OF RHEUMATOLOGY | AMERICAN COLLEGE OF RHEUMATOLOGY | $8.0M | Apr 21, 2025 | 2025Q1 | HCRBUDMMM |
| TODD STRATEGY GROUP | ALEXION PHARMACEUTICALS, INC. | $8.0M | Apr 21, 2025 | 2025Q1 | MMMHCR |
| ARTHRITIS FOUNDATION | ARTHRITIS FOUNDATION | $7.5M | Jul 17, 2025 | 2025Q2 | MMMHCRBUD |
| ARTHRITIS FOUNDATION | ARTHRITIS FOUNDATION | $7.5M | Apr 18, 2025 | 2025Q1 | MMMHCRBUD |
| THE KPM GROUP DC LLC | THE HS COALITION | $7.0M | Jul 17, 2025 | 2025Q2 | PHA |
| EMERGENT STRATEGIES | PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION | $6.0M | Jul 21, 2025 | 2025Q2 | PHA |
| EPILEPSY FOUNDATION | EPILEPSY FOUNDATION | $6.0M | Jul 21, 2025 | 2025Q2 | BUDHCRCIV |
| TODD STRATEGY GROUP | PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | $6.0M | Jul 20, 2025 | 2025Q2 | PHAMMM |
| TODD STRATEGY GROUP | JOHNSON & JOHNSON SERVICES, INC. | $6.0M | Jul 19, 2025 | 2025Q2 | HCR |
| THE NICKLES GROUP, LLC | UCB, INC. | $6.0M | Jul 10, 2025 | 2025Q2 | MMMTAXHCR |
| TODD STRATEGY GROUP | PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | $6.0M | Apr 21, 2025 | 2025Q1 | MMMPHA |
| TODD STRATEGY GROUP | JOHNSON & JOHNSON SERVICES, INC. | $6.0M | Apr 21, 2025 | 2025Q1 | HCR |
| EMERGENT STRATEGIES | PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION | $6.0M | Apr 21, 2025 | 2025Q1 | PHA |
| THE NICKLES GROUP, LLC | UCB, INC. | $6.0M | Apr 21, 2025 | 2025Q1 | MMMTAXHCR |
| TODD STRATEGY GROUP | EMD SERONO INC. | $5.0M | Jul 19, 2025 | 2025Q2 | PHAHCR |
| ARTEMIS POLICY GROUP LLC | NATIONAL BLEEDING DISORDER FOUNDATION (FKA NATIONAL HEMOPHILIA FOUNDATION) | $5.0M | Jul 18, 2025 | 2025Q2 | MMMHCRINS |
| TODD STRATEGY GROUP | EMD SERONO INC. | $5.0M | Apr 21, 2025 | 2025Q1 | PHAHCR |
| TODD STRATEGY GROUP | MERCK & CO., INC. | $4.0M | Jul 20, 2025 | 2025Q2 | HCRMMM |
| ARTEMIS POLICY GROUP LLC | SUSAN G. KOMEN | $4.0M | Jul 18, 2025 | 2025Q2 | BUDINSMMM |
| THE KPM GROUP DC LLC | ASTRIA THERAPEUTICS, INC. | $4.0M | Jul 17, 2025 | 2025Q2 | PHA |
| VENABLE LLP | PATIENT ACCESS NETWORK FOUNDATION | $4.0M | Jul 3, 2025 | 2025Q2 | HCR |
| ARTEMIS POLICY GROUP LLC | SUSAN G. KOMEN | $4.0M | Apr 21, 2025 | 2025Q1 | BUDINSMMM |
| THE KPM GROUP DC LLC | ASTRIA THERAPEUTICS, INC. | $4.0M | Apr 21, 2025 | 2025Q1 | PHA |
| TODD STRATEGY GROUP | MERCK & CO., INC. | $4.0M | Apr 21, 2025 | 2025Q1 | HCRMMM |
| LMH STRATEGIC SOLUTIONS | GLAXOSMITHKLINE LLC | $4.0M | Apr 18, 2025 | 2025Q1 | HCRPHA |
| VENABLE LLP | PATIENT ACCESS NETWORK FOUNDATION | $4.0M | Apr 7, 2025 | 2025Q1 | HCR |
| THE ALS ASSOCIATION | THE ALS ASSOCIATION | $3.0M | Jul 22, 2025 | 2025Q2 | VETTAXHCR |
| THE ALS ASSOCIATION | THE ALS ASSOCIATION | $3.0M | Apr 20, 2025 | 2025Q1 | BUDHCRMMM |
| SPANGLER STRATEGIES LLC | AMERICAN BANKERS ASSOCIATION | $2.0M | Jul 17, 2025 | 2025Q2 | TAXCSP |
| SPANGLER STRATEGIES LLC | AMERICAN BANKERS ASSOCIATION | $2.0M | Apr 18, 2025 | 2025Q1 | TAXCSP |
| NATIONAL PSORIASIS FOUNDATION | NATIONAL PSORIASIS FOUNDATION | Undisclosed | Jun 2, 2025 | 2025Q1 | HCRMMM |
| JNJ |
| JOHNSON & JOHNSON |
| Buy |
| Mar 5, 2025 |
| $15,001 - $50,000 |
| Same day |
| JOHNSON & JOHNSON SERVICES, INC. |
| 36% |
| Lloyd Doggett | D | JNJ | JOHNSON & JOHNSON | Buy | Mar 4, 2025 | $1,001 - $15,000 | 1d before | JOHNSON & JOHNSON SERVICES, INC. | 35% |
| Lloyd Doggett | D | JNJ | JOHNSON & JOHNSON | Buy | Mar 4, 2025 | $1,001 - $15,000 | 1d before | JOHNSON & JOHNSON SERVICES INC | 35% |
| Bruce Westerman | R | JNJ | JOHNSON & JOHNSON | Buy | Mar 3, 2025 | $1,001 - $15,000 | 2d before | JOHNSON & JOHNSON SERVICES, INC. | 37% |
| Bruce Westerman | R | JNJ | JOHNSON & JOHNSON | Buy | Mar 3, 2025 | $1,001 - $15,000 | 2d before | JOHNSON & JOHNSON SERVICES INC | 37% |
| Bruce Westerman | R | PFE | PFIZER INC | Buy | Mar 3, 2025 | $1,001 - $15,000 | 2d before | PFIZER INC. | 37% |
| Bruce Westerman | R | MRK | Merck & Co., Inc. | Buy | Mar 3, 2025 | $1,001 - $15,000 | 2d before | MERCK & CO., INC. | 37% |
| Josh Gottheimer | D | JNJ | JOHNSON & JOHNSON | Sell | Mar 7, 2025 | $1,001 - $15,000 | 2d after | JOHNSON & JOHNSON SERVICES, INC. | 31% |
| Josh Gottheimer | D | JNJ | JOHNSON & JOHNSON | Sell | Mar 7, 2025 | $1,001 - $15,000 | 2d after | JOHNSON & JOHNSON SERVICES INC | 31% |
| Carol D. Miller | R | PFE | PFIZER INC | Sell | Mar 10, 2025 | $1,001 - $15,000 | 5d after | PFIZER INC. | 38% |
| Gilbert Ray Cisneros, Jr. | D | PFE | PFIZER INC | Buy | Feb 26, 2025 | $1,001 - $15,000 | 7d before | PFIZER INC. | 36% |
| Gilbert Ray Cisneros, Jr. | D | MRK | Merck & Co., Inc. | Buy | Feb 26, 2025 | $15,001 - $50,000 | 7d before | MERCK & CO., INC. | 36% |
| Robert P. Bresnahan, Jr. | R | MRK | Merck & Co., Inc. | Sell | Feb 25, 2025 | $15,001 - $50,000 | 8d before | MERCK & CO., INC. | 41% |
| Robert P. Bresnahan, Jr. | R | PFE | PFIZER INC | Buy | Feb 25, 2025 | $15,001 - $50,000 | 8d before | PFIZER INC. | 41% |
| Robert P. Bresnahan, Jr. | R | ABBV | AbbVie Inc. | Buy | Feb 25, 2025 | $1,001 - $15,000 | 8d before | ABBVIE INC. | 37% |
| Jefferson Shreve | R | ABBV | AbbVie Inc. | Buy | Feb 24, 2025 | Pending | 9d before | ABBVIE INC. | 36% |
| Jefferson Shreve | R | PFE | PFIZER INC | Buy | Feb 24, 2025 | $15,001 - $50,000 | 9d before | PFIZER INC. | 36% |
| Jefferson Shreve | R | JNJ | JOHNSON & JOHNSON | Buy | Feb 24, 2025 | $15,001 - $50,000 | 9d before | JOHNSON & JOHNSON SERVICES, INC. | 36% |
| Jefferson Shreve | R | JNJ | JOHNSON & JOHNSON | Buy | Feb 24, 2025 | $15,001 - $50,000 | 9d before | JOHNSON & JOHNSON SERVICES INC | 36% |
| Jefferson Shreve | R | MRK | Merck & Co., Inc. | Buy | Feb 24, 2025 | $15,001 - $50,000 | 9d before | MERCK & CO., INC. | 36% |
| Jefferson Shreve | R | ABBV | AbbVie Inc. | Buy | Feb 24, 2025 | $50,001 - $100,000 | 9d before | ABBVIE INC. | 36% |
| Sheri Biggs | R | JNJ | JOHNSON & JOHNSON | Sell | Mar 19, 2025 | $15,001 - $50,000 | 14d after | JOHNSON & JOHNSON SERVICES INC | 18% |
| Sheri Biggs | R | MRK | Merck & Co., Inc. | Sell | Mar 19, 2025 | $15,001 - $50,000 | 14d after | MERCK & CO., INC. | 18% |
| Sheri Biggs | R | JNJ | JOHNSON & JOHNSON | Sell | Mar 19, 2025 | $15,001 - $50,000 | 14d after | JOHNSON & JOHNSON SERVICES, INC. | 18% |
| Kelly Morrison | D | MRK | Merck & Co., Inc. | Sell | Mar 20, 2025 | $1,001 - $15,000 | 15d after | MERCK & CO., INC. | 23% |
| George Whitesides | D | JNJ | JOHNSON & JOHNSON | Sell | Mar 24, 2025 | $100,001 - $250,000 | 19d after | JOHNSON & JOHNSON SERVICES INC | 41% |
| George Whitesides | D | NVS | NOVARTIS AG | Sell | Mar 24, 2025 | $100,001 - $250,000 | 19d after | NOVARTIS | 41% |
| George Whitesides | D | JNJ | JOHNSON & JOHNSON | Sell | Mar 24, 2025 | $100,001 - $250,000 | 19d after | JOHNSON & JOHNSON SERVICES, INC. | 41% |
| John Boozman | R | PFE | PFIZER INC | Sell | Feb 13, 2025 | $1,001 - $15,000 | 20d before | PFIZER INC. | 36% |
| John Boozman | R | PFE | PFIZER INC | Sell | Feb 13, 2025 | $1,001 - $15,000 | 20d before | PFIZER INC. | 36% |
| Julie Johnson | D | PFE | PFIZER INC | Sell | Feb 12, 2025 | $1,001 - $15,000 | 21d before | PFIZER INC. | 36% |
| Gilbert Ray Cisneros, Jr. | D | JNJ | JOHNSON & JOHNSON | Buy | Mar 31, 2025 | $15,001 - $50,000 | 26d after | JOHNSON & JOHNSON SERVICES INC | 36% |
| Gilbert Ray Cisneros, Jr. | D | MRK | Merck & Co., Inc. | Sell | Mar 31, 2025 | $15,001 - $50,000 | 26d after | MERCK & CO., INC. | 36% |
| Gilbert Ray Cisneros, Jr. | D | JNJ | JOHNSON & JOHNSON | Buy | Mar 31, 2025 | $15,001 - $50,000 | 26d after | JOHNSON & JOHNSON SERVICES, INC. | 36% |
| Gilbert Ray Cisneros, Jr. | D | PFE | PFIZER INC | Sell | Mar 31, 2025 | $15,001 - $50,000 | 26d after | PFIZER INC. | 36% |
| Julie Johnson | D | JNJ | JOHNSON & JOHNSON | Sell | Apr 1, 2025 | $1,001 - $15,000 | 27d after | JOHNSON & JOHNSON SERVICES INC | 36% |
| Julie Johnson | D | JNJ | JOHNSON & JOHNSON | Sell | Apr 1, 2025 | $1,001 - $15,000 | 27d after | JOHNSON & JOHNSON SERVICES, INC. | 36% |
| Josh Gottheimer | D | ABBV | AbbVie Inc. | Buy | Apr 1, 2025 | $1,001 - $15,000 | 27d after | ABBVIE INC. | 36% |
| Dwight Evans | D | ABBV | AbbVie Inc. | Sell | Apr 3, 2025 | $1,001 - $15,000 | 29d after | ABBVIE INC. | 27% |
| Josh Gottheimer | D | ABBV | AbbVie Inc. | Buy | Apr 3, 2025 | $1,001 - $15,000 | 29d after | ABBVIE INC. | 27% |
| Dwight Evans | D | ABBV | AbbVie Inc. | Buy | Apr 3, 2025 | $1,001 - $15,000 | 29d after | ABBVIE INC. | 27% |
| Jared Moskowitz | D | ABBV | AbbVie Inc. | Buy | Apr 7, 2025 | $1,001 - $15,000 | 33d after | ABBVIE INC. | 36% |
| Jared Moskowitz | D | ABBV | AbbVie Inc. | Buy | Apr 7, 2025 | $1,001 - $15,000 | 33d after | ABBVIE INC. | 36% |
| Robert P. Bresnahan, Jr. | R | PFE | PFIZER INC | Sell | Apr 8, 2025 | $15,001 - $50,000 | 34d after | PFIZER INC. | 41% |
| Robert P. Bresnahan, Jr. | R | MRK | Merck & Co., Inc. | Buy | Apr 8, 2025 | $15,001 - $50,000 | 34d after | MERCK & CO., INC. | 41% |
| Robert P. Bresnahan, Jr. | R | K | K | Buy | Apr 8, 2025 | $1,001 - $15,000 | 34d after | AMERICAN BANKERS ASSOCIATION | 37% |
| Robert P. Bresnahan, Jr. | R | ABBV | AbbVie Inc. | Sell | Apr 8, 2025 | $1,001 - $15,000 | 34d after | ABBVIE INC. | 37% |
| Robert P. Bresnahan, Jr. | R | ABBV | AbbVie Inc. | Sell | Apr 8, 2025 | $1,001 - $15,000 | 34d after | ABBVIE INC. | 37% |
| Robert P. Bresnahan, Jr. | R | JNJ | JOHNSON & JOHNSON | Sell | Apr 8, 2025 | $1,001 - $15,000 | 34d after | JOHNSON & JOHNSON SERVICES INC | 37% |
| Robert P. Bresnahan, Jr. | R | JNJ | JOHNSON & JOHNSON | Sell | Apr 8, 2025 | $1,001 - $15,000 | 34d after | JOHNSON & JOHNSON SERVICES, INC. | 37% |
| Robert P. Bresnahan, Jr. | R | K | K | Buy | Apr 8, 2025 | $1,001 - $15,000 | 34d after | AMERICAN CANCER SOCIETY CANCER ACTION NETWORK INC | 37% |
| Robert P. Bresnahan, Jr. | R | K | K | Buy | Apr 8, 2025 | $1,001 - $15,000 | 34d after | NATIONAL BLEEDING DISORDER FOUNDATION (FKA NATIONAL HEMOPHILIA FOUNDATION) | 37% |
| Robert P. Bresnahan, Jr. | R | K | K | Buy | Apr 8, 2025 | $1,001 - $15,000 | 34d after | SUSAN G. KOMEN | 37% |
| Robert P. Bresnahan, Jr. | R | K | K | Buy | Apr 8, 2025 | $1,001 - $15,000 | 34d after | GSK (FKA GLAXOSMITHKLINE INC.) | 37% |
| Robert P. Bresnahan, Jr. | R | K | K | Buy | Apr 8, 2025 | $1,001 - $15,000 | 34d after | GLAXOSMITHKLINE LLC | 37% |
| Robert P. Bresnahan, Jr. | R | K | K | Buy | Apr 8, 2025 | $1,001 - $15,000 | 34d after | THE SUSAN G. KOMEN BREAST CANCER FOUNDATION, INC. DBA SUSAN G. KOMEN | 37% |
| Robert P. Bresnahan, Jr. | R | K | K | Buy | Apr 8, 2025 | $1,001 - $15,000 | 34d after | MERCK & CO., INC. | 37% |
| Robert P. Bresnahan, Jr. | R | K | K | Buy | Apr 8, 2025 | $1,001 - $15,000 | 34d after | PATIENT ACCESS NETWORK FOUNDATION | 37% |
| Josh Gottheimer | D | JNJ | JOHNSON & JOHNSON | Sell | Apr 9, 2025 | $1,001 - $15,000 | 35d after | JOHNSON & JOHNSON SERVICES INC | 36% |
| Josh Gottheimer | D | JNJ | JOHNSON & JOHNSON | Sell | Apr 9, 2025 | $1,001 - $15,000 | 35d after | JOHNSON & JOHNSON SERVICES, INC. | 36% |
| Julie Johnson | D | ALE | ALE | Sell | Jan 28, 2025 | $1,001 - $15,000 | 36d before | ALEXION PHARMACEUTICALS, INC. | 18% |
| Julie Johnson | D | ALE | ALE | Sell | Jan 28, 2025 | $1,001 - $15,000 | 36d before | ALEXION PHARMACEUTICALS, INC. | 18% |
| Jefferson Shreve | R | PFE | PFIZER INC | Sell | Apr 11, 2025 | $15,001 - $50,000 | 37d after | PFIZER INC. | 32% |
| Josh Gottheimer | D | MRK | Merck & Co., Inc. | Sell | Jan 27, 2025 | $15,001 - $50,000 | 37d before | MERCK & CO., INC. | 20% |
| Gilbert Ray Cisneros, Jr. | D | K | K | Buy | Jan 24, 2025 | $1,001 - $15,000 | 40d before | GLAXOSMITHKLINE LLC | 32% |
| Gilbert Ray Cisneros, Jr. | D | JNJ | JOHNSON & JOHNSON | Sell | Jan 24, 2025 | $1,001 - $15,000 | 40d before | JOHNSON & JOHNSON SERVICES INC | 32% |
| Gilbert Ray Cisneros, Jr. | D | JNJ | JOHNSON & JOHNSON | Sell | Jan 24, 2025 | $1,001 - $15,000 | 40d before | JOHNSON & JOHNSON SERVICES, INC. | 32% |
| Gilbert Ray Cisneros, Jr. | D | MRK | Merck & Co., Inc. | Sell | Jan 24, 2025 | $1,001 - $15,000 | 40d before | MERCK & CO., INC. | 32% |
| Gilbert Ray Cisneros, Jr. | D | PFE | PFIZER INC | Sell | Jan 24, 2025 | $1,001 - $15,000 | 40d before | PFIZER INC. | 32% |
| Gilbert Ray Cisneros, Jr. | D | K | K | Buy | Jan 24, 2025 | $1,001 - $15,000 | 40d before | PATIENT ACCESS NETWORK FOUNDATION | 32% |
| Gilbert Ray Cisneros, Jr. | D | K | K | Buy | Jan 24, 2025 | $1,001 - $15,000 | 40d before | MERCK & CO., INC. | 32% |
| Gilbert Ray Cisneros, Jr. | D | K | K | Buy | Jan 24, 2025 | $1,001 - $15,000 | 40d before | THE SUSAN G. KOMEN BREAST CANCER FOUNDATION, INC. DBA SUSAN G. KOMEN | 32% |
| Gilbert Ray Cisneros, Jr. | D | K | K | Buy | Jan 24, 2025 | $1,001 - $15,000 | 40d before | AMERICAN BANKERS ASSOCIATION | 32% |
| Gilbert Ray Cisneros, Jr. | D | K | K | Buy | Jan 24, 2025 | $1,001 - $15,000 | 40d before | AMERICAN CANCER SOCIETY CANCER ACTION NETWORK INC | 32% |
| Gilbert Ray Cisneros, Jr. | D | K | K | Buy | Jan 24, 2025 | $1,001 - $15,000 | 40d before | NATIONAL BLEEDING DISORDER FOUNDATION (FKA NATIONAL HEMOPHILIA FOUNDATION) | 32% |
| Gilbert Ray Cisneros, Jr. | D | K | K | Buy | Jan 24, 2025 | $1,001 - $15,000 | 40d before | SUSAN G. KOMEN | 32% |
| Gilbert Ray Cisneros, Jr. | D | K | K | Buy | Jan 24, 2025 | $1,001 - $15,000 | 40d before | GSK (FKA GLAXOSMITHKLINE INC.) | 32% |
| Josh Gottheimer | D | JNJ | JOHNSON & JOHNSON | Buy | Jan 24, 2025 | $1,001 - $15,000 | 40d before | JOHNSON & JOHNSON SERVICES, INC. | 31% |
| Josh Gottheimer | D | JNJ | JOHNSON & JOHNSON | Buy | Jan 24, 2025 | $1,001 - $15,000 | 40d before | JOHNSON & JOHNSON SERVICES INC | 31% |
| Julia Letlow | R | ABBV | AbbVie Inc. | Sell | Jan 24, 2025 | $1,001 - $15,000 | 40d before | ABBVIE INC. | 31% |
| Josh Gottheimer | D | JNJ | JOHNSON & JOHNSON | Buy | Jan 21, 2025 | $1,001 - $15,000 | 43d before | JOHNSON & JOHNSON SERVICES INC | 36% |
| Josh Gottheimer | D | JNJ | JOHNSON & JOHNSON | Buy | Jan 21, 2025 | $1,001 - $15,000 | 43d before | JOHNSON & JOHNSON SERVICES, INC. | 36% |
| Jefferson Shreve | R | ABBV | AbbVie Inc. | Sell | Apr 17, 2025 | Pending | 43d after | ABBVIE INC. | 14% |
| Jefferson Shreve | R | MRK | Merck & Co., Inc. | Sell | Apr 17, 2025 | $15,001 - $50,000 | 43d after | MERCK & CO., INC. | 14% |
| Jefferson Shreve | R | ABBV | AbbVie Inc. | Sell | Apr 17, 2025 | $50,001 - $100,000 | 43d after | ABBVIE INC. | 14% |
| Josh Gottheimer | D | ABBV | AbbVie Inc. | Sell | Apr 17, 2025 | $1,001 - $15,000 | 43d after | ABBVIE INC. | 14% |
| Julie Johnson | D | MRK | Merck & Co., Inc. | Buy | Jan 17, 2025 | $1,001 - $15,000 | 47d before | MERCK & CO., INC. | 31% |
| Bruce Westerman | R | PFE | PFIZER INC | Sell | Apr 21, 2025 | $1,001 - $15,000 | 47d after | PFIZER INC. | 14% |
| Bruce Westerman | R | JNJ | JOHNSON & JOHNSON | Sell | Apr 21, 2025 | $1,001 - $15,000 | 47d after | JOHNSON & JOHNSON SERVICES, INC. | 14% |
| Bruce Westerman | R | JNJ | JOHNSON & JOHNSON | Sell | Apr 21, 2025 | $1,001 - $15,000 | 47d after | JOHNSON & JOHNSON SERVICES INC | 14% |
| Bruce Westerman | R | MRK | Merck & Co., Inc. | Sell | Apr 21, 2025 | $1,001 - $15,000 | 47d after | MERCK & CO., INC. | 14% |
| Josh Gottheimer | D | JNJ | JOHNSON & JOHNSON | Buy | Jan 16, 2025 | $1,001 - $15,000 | 48d before | JOHNSON & JOHNSON SERVICES, INC. | 36% |
| Josh Gottheimer | D | JNJ | JOHNSON & JOHNSON | Buy | Jan 16, 2025 | $1,001 - $15,000 | 48d before | JOHNSON & JOHNSON SERVICES INC | 36% |
| Byron Donalds | R | MRK | Merck & Co., Inc. | Sell | Jan 16, 2025 | $1,001 - $15,000 | 48d before | MERCK & CO., INC. | 36% |
| Byron Donalds | R | MRK | Merck & Co., Inc. | Sell | Jan 16, 2025 | $1,001 - $15,000 | 48d before | MERCK & CO., INC. | 36% |
| Jared Moskowitz | D | ABBV | AbbVie Inc. | Buy | Jan 15, 2025 | $1,001 - $15,000 | 49d before | ABBVIE INC. | 36% |
| Jared Moskowitz | D | MRK | Merck & Co., Inc. | Sell | Jan 15, 2025 | $1,001 - $15,000 | 49d before | MERCK & CO., INC. | 36% |
| Jared Moskowitz | D | ABBV | AbbVie Inc. | Buy | Jan 15, 2025 | $1,001 - $15,000 | 49d before | ABBVIE INC. | 36% |
| Julie Johnson | D | PFE | PFIZER INC | Sell | Jan 15, 2025 | $1,001 - $15,000 | 49d before | PFIZER INC. | 36% |